This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, DigiHealth, MedTech, M&A, Biosimilar, Animal Health & Biotech. Check out our full report below:

Formosa Reports Top-Line Data from P-III (CPN-303) Study of APP13007 for Inflammation and Pain Post Cataract Surgery in Chinese Patients

Read More: Formosa Pharmaceuticals

Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes

Read More: Cytoki Pharma

Xencor Reports the First Individual Dosing with XmAb942 in P-I/II Trial to Treat Inflammatory Bowel Disease

Read More: Xencor

Zymeworks Reports the First Patient Dosing with ZW191 in P-I Study for Treating Folate Receptor-⍺ Expressing Advanced Solid Tumors

Read More: Zymeworks

Minghui Pharmaceutical Reports Initial Data from P-I Study of MHB039A for R/R Solid Tumors

Read More: Minghui Pharmaceutical

OncoResponse Reports P-I Study Results of OR502 for the Treatment of Advanced Cancer

Read More: OncoResponse

AstraZeneca Reports Data from the P-III (WAYPOINT) Study of Tezspire (Tezepelumab) for Chronic Rhinosinusitis with Nasal Polyps

Read More: AstraZeneca

Ionis Reports the US FDA’s NDA Acceptance of Donidalorsen as a Prophylactic Treatment of Hereditary Angioedema (HAE)

Read More: Ionis

Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)

Read More: Sanofi and Regeneron

Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma

Read More: Leads Biolabs

ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)

Read More: ARTHEx Biotech

Cumberland Pharmaceuticals’ Ifetroban Secures the US FDA’s ODD and RPDD for Duchenne Muscular Dystrophy

Read More: Cumberland Pharmaceuticals

Dizal Reports the Regulatory Submission of Sunvozertinib to the US FDA for Treating R/R Non-Small Cell Lung Cancer

Read More: Dizal

AskBio’s AB-1003 Secures the US FDA’s Rare Pediatric Disease and Orphan Drug Designations to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9

Read More: AskBio

AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

Read More: AbbVie and EvolveImmune Therapeutics

Surrozen Collaborates with TCGFB for Developing TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Read More: Surrozen and TCGFB

Ascendis Pharma Join Forces with Novo Nordisk to Develop and Commercialize TransCon Tech-based Products in Metabolic and Cardiovascular Indications

Read More: Ascendis Pharma and Novo Nordisk

Inocras and Summit Pharmaceuticals International Corporation Join Forces to Advance Healthcare in Japan

Read More: Inocras and Summit Pharmaceuticals

Naitive Technologies Join Forces with Parvizi Surgical Innovation to Advance Osteoporosis Detection

Read More: Naitive Technologies and Parvizi Surgical Innovation

Aditum Bio and Leads Biolabs Launch Oblenio Bio to Advance LBL-051 for Autoimmune Indications

Read More: Aditum Bio and Leads Biolabs

Medable Collaborates with Google Cloud to Offer Digital Clinical Trials Technology on Google Cloud Marketplace

Read More: Medable and Google Cloud

Abbott Reports 2 Years Data from the LIFE-BTK Study of Esprit BTK System to Treat Peripheral Artery Disease Below the Knee

Read More: Abbott

Johnson & Johnson MedTech Reports the US FDA’s Approval of VARIPULSE Pulsed Field Ablation Platform to Treat Atrial Fibrillation

Read More: Johnson & Johnson

Jade Biosciences Reverse Merges with Aerovate Therapeutics to Advance Standard of Care for Autoimmune Diseases

Read More: Jade Biosciences and Aerovate Therapeutics

Boston Scientific Reports the Acquisition of Cortex

Read More: Boston Scientific and Cortex

GHO Capital Partners and Ampersand Capital Partners Report the Acquisition of Avid Bioservices for ~$1.1B

Read More: GHO Capital Partners, Ampersand Capital & Avid Bioservices

Meitheal Pharmaceuticals Receives Exclusive Commercial Rights of Three Biosimilars Across the US

Read More: Meitheal Pharmaceuticals

Alvotech and Advanz Pharma Reports the EMA’s MAA Acceptance of AVT05 (Biosimilar, Simponi)

Read More: Alvotech and Advanz Pharma

Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs

Read More: Jaguar Health

Pheast Therapeutics Highlights Preclinical Data of PHST001 at SITC 2024

Read More: Pheast Therapeutics

Related Post: PharmaShots Weekly Snapshots (October 28 – October 30, 2024)